METHODS	Using a double-blind procedure , 144 patients selected as chronic users of one of 3 BZD lorazepam , alprazolam or bromazepam ( duration of use > 6 months ; regular dose > or = 3 mg lorazepam equivalent ) and with clinical remission ( score on Hamilton-Anxiety < 14 ; Raskin-Depression < 6 ) had entered a controlled study ( versus placebo ) and were randomized in two parallel groups .\